. >>> merck's ceo speaks out. we'll bring i his commenyou his straig comments straight ahead. >>> and the one sector that could see hot returns in these cold temperatures. it's tuesday, november 9, 2018 "worldwide exchange" begins now. good morning welcome to "worldwide exchange." i'm wilfred frost. >> i'm seema mody in for sara eisen. >> good morning. the big story that has everyone buzzing, alabama's dramatic overtile win ovove overtime win in georgia. more on that story coming up but congratulations to them. commiserations to the losing side first, let's get back to the market picture we did have plenty of record highs intraday yesterday but not all record closes. the dow did close slightly lower for the day. the s&p and the nasdaq were slightly higher. the nasdaq led the charge, up 0.3% gains were slight but they were broad, 9 out of 11 s&p sectors were higher. utilities were the best performing of them and that highlights the boring fle ing n the outperformance ten-year treasury note for you, yields rose yest

these are strong i think that merck's a buy here. merck has got a 3% yield people have overlooked that stock in the great rotation into the cyclicals. i think there are a lot of things that are is on the bad. >> right, but the corollary is that the good performers are too expensive to a large degree. >> i want the good performers to cool off a downgrade of illinois toolworks, cwhich i thought was unfortunate, it's got 8 to 10% growth they're worried about auto and construction of course, i'm worried that auto and construction are too hot but these are the stocks -- there's a parker hanafan upgrade i like i need to see the banks on fire. that's what i want i need leadership from jpmorgan wells fargo had a problem. i forget what it was was it stagecoach related? they opened some accounts -- >> there was some cross-selling going on

vonnie: merck is up 7%. thank you. stock we are watching, general electric shares are down thanwing -- fallen by more 2% today. it's taking a $6.2 billion charge in q4 because of lingering problems in its insurance business. the ceo said at a time when we are moving forward as a company a charge of this magnitude from isegacy insurance portfolio deeply disappointing. brooke sutherland joins us now. column entitled expect more ugly ge surprises. >> that is sort of what people were thinking after you had the third-quarter earnings report where you have to dramatically and you hadguidance november where they had to cut the dividend and dramatically reduce 2018 guidance. a lot of people at that point the worst is behind us. an increasing concern about ge capital. behemoth.ill a one analyst puts it is still a top 20 u.s. bank with over 140 billion in assets. this is huge and it is very opaque in nature. we don't know everything that's in here as evidenced by the extent of the charge they are taking and there could still be

maria: i also spoke with the ceo of merck. when i spoke with ken frazier he gave me an update on the progress they are making in the fight against cancer. >> if the american cancer society put out data showing the death rates of cancer has declined by 25% since 1991. a large part of that is the kind of treatments we have. these are the leading killers. prostate cancer. keytruda is approved for newly diagnosed lung cancer patients. maria: you have got such an incredible performance with that drug. but people want to know if you need to make that business bigger. you have got a tax plan putting more money in your pocket in terms of corporate. >> the most of important thing about the tax plan is it puts american companies on an even playing field with our outside u.s. competition. that's really important. with respect to the money that can be repatriated at reasonable rates, i don't think it will change our strategy. we have always been a company look for good science and acquisitions that would allow to us innovate. i don't thin

anything competitive for merck creates risk for merck., less dependent on the one drug because they have another drug that is a key driver, but merck is the most exposed if roche continues to deliver strong clinical trials in its lung cancer space. guy: other areas? give me a sense of m&a? what factors can we think about when it comes to the dollar. a lot of these pharmas reporting dollars. what can we expect in these factors? sam: let's talk about m&a first. roche closed the year with an m&a deal. we saw a few, not as many as thected, but roche ending last trading day of the year, announcing the acquisition of the u.s. biotech. nothing of russian size, but it got people excited again and we have the big health care conference that jpmorgan holds next week and everyone is deals, etc. you will continue to see cherub pharma among large small biotech's, but in terms of wholesale m&a, that will still end up being dependent on assets and specific needs of the pharma companies. science coming more in focus. sam: entirely. volatility is so much

it's a small fraction of the overall revenue, so don't mistake a merck or a pfizer or even a bristol for a bio technology stock like a serepta that can triple in a year or lexion that can double in a year just know what to expect if you get 10% from merck plus 3%, that's great be happy with it >> do we need to focus more on health care this year than we otherwise are thinking >> i think the opportunity with repatriation to see finally an uptick in m and a is there for health care, so yes, i think investors should be paying more attention to it. >> i would expect more and more, too. we obviously know all the rumor just from yesterday with celge e celgene, but it sort of faded. >> kind of a lame move for an upgrade, isn't it? >> well, the stock yesterday >> lost 57 bucks saw some unusual activity. it shot through 60 yesterday to 62. so the move was really yesterday. i think it kind of wore out a lot of the buyers. >> you're looking at the chart there. the 24 hour chart is pretty telling. back to headquarters now to sue herera, who has the latest headlines for us hi, sue. >> indeed, i d

at merck, we're not committed just to one area of medicine or another.we're committed to finding great drugs. >> kelly, you have a question? >> meg, thank you. mr. frazier, appreciate you joining us i was going to ask in light of everything that's happened with drug prices in the country the last couple years, we reported amazon has looked at getting into the pharmacy business do you think amazon's entry could be good for consumers? and would you embrace that as a drug delivery model? >> well, i don't know exactly what amazon has in mind. that's in the drigs side of the business we're focused on our business bringing new innovative differentiated medicines to market for conditions like alzheimer's and important conditions like cancer so if that's a more efficient way of getting drugs to patients, we would be in favor of it. >> as we think about drug pricing, of course -- oh, sorry, go ahead, kelly. >> sure, i was just going to quickly ask as a follow-up to that is there something broken with the drug distribution model l in this country as it currently s

that highlights the asymmetric risk or the exposure that merck has to this one drug.is from a similar drug. a lot of indications are already in the bag. it's all about the question of how much growth they will get out of these products. vonnie: what about the smaller companies that may have one product potentially coming to market? will we see a lot of acquisition on the part of bigger companies? sam: that is certainly the hope 2017 andh investors in continues to be the case in 2018. what we saw in 2017 wasn't a lot of m&a in this space. the very end of the year when they bought a small company called igniter. it is in the oncology space. i expect to see the same kinds of things, pharma companies going after these smaller biotechs in a controlled fashion. stretched are often to a level that sometimes the market already is pricing in a valuation premium or m&a premium. mark: no megadeals among the big boys? sam: probably not in 2018. pfizer is still trying to trim its business. they are selling their consumer business. they are looking to spin it off. they have to get

, the old saint merck down 4% thp 2017 was the key of key truda, the big anti-cancer drug that worksthan most, but remember the economy is so hot that pretty much every active portfolio manager fled the drug stocks in order to buyer mo of the cyclicals. merck was casually the rotation, although there was a time when this company had so many irons in the fire that the stock could have transcended the business cycle. not anymore, but it has the safe 3.4% yield and some nice protection the dow's third weakest performer, exxonmobil off 7% before we chock up to exxon being an oil company, get this, get this, chevron was up more than 6%. the difference chevron had big projects coming online and of the booed productiboosted production i've gotten less enthusiastic about the group because i fear one day the fossil fuel industry will be the equivalent of big tobacco. when the millennials start running money that's what they'll do magellan partners which works 5% yield and transports crude from the pipeline star premium basin. hey, it's needed it just doesn't have the growth to get me excited,

. >> it has emerged as a front runner to purchase merck's.opped out of the sale process. it is seeking to divest is vitamin and food supplement business in order to focus on pharmaceuticals. why does nestle need this consumer health business? >> it is a good time for this right now. for nestle, under the new ceo, mark schneider, and it has been just over a year since he took over. they have been shifting focus and going more into health care. schneider is a health care industry man. they have been looking at these spaces that nestle has not spent much time in lately. in december, they did their biggest deal in 11 years when they purchased atrium innovation. a little known supplements maker. and now, the priest had we are talking about, $5 billion for merck would be almost double what they paid on their last -- the price we are talking about, $5 billion for merck would be almost double what they paid on their last deal. >> walmart has announced it is boosting starting wages to $11 an hour and pay and bonuses up to $1000. america's largest empl

mark: nestle has emerged as a front runner to purchase merck's consumer health unit.opped out of the sale process. merck is looking to divest its food and vitamin is this to focus on pharmaceuticals. why does nestle need this consumer health business? >> it is the maker of nutritional supplements, which is good right now. for nestle, under the new ceo mark schneider, and it has been just over a year since he took over, they have been shifting focus and going more into health care. schneider is a german health care industry man. they have been looking at these spaces that nestle has not spent much time on earlier. in fact, in december, they did their biggest deal in 11 years when they bought aetrium innovation. a little known supplements maker. now, the price tag we are talking about, $5 billion for merck would be almost double what they paid on their last deal. david: walmart has announced it is boosting starting wages to $11 an hour and paying bonuses up to $1000. america's largest employer is crediting tax cuts for these pay increases. a big announcement because it'

mark: what does merck do with the money? a look at more acquisitions in the space it is their core focus remains to be seen. mark: anymore deals in this industry? >> absolutely. you saw the approach for the belgian company which was rejected. and it seems like there's a lot going on. and it seems like there's a lot going on. the health care conference happening in san francisco right now. one would imagine more deals coming out of that. companies looking at their portfolio and deciding what they want to get rid of. thanks for filling us in in what's going on on m&a today. still ahead, u.k. administers are making the case for a financial services deal to a skeptical germany. with the berlin latest. this is bloomberg. ♪ mark: i'm mark barton. this is bloomberg markets. vonnie: live from new york, i'm vonnie quinn. time for a look at the bloomberg business flash. archer hathaway has named two potential successors to see a warren buffett as directors. -- berkshire hathaway has named two potential successors to ceo warren buffett

maria: there is an oncology at merck. we'll talk to ken frazier tomorrow. almost more consolidation in this area. for merck to compete with some of the other major cancer operations out there, it could mean an acquisition in the future. i want to get your take on this other story today. two major apple invest there is calling on apple among children, teenagers. the california state teachers retirement system cajoling about $2 billion in apple stock and they are the ones to develop more sophisticated parental controls to study the impact of overuse of mental health. here's the first, sean parker had to say about this last fall about the impact of social media and children's mental health. >> god only knows what it is doing to our children. exactly the kind of thing that a hacker like myself would come up with because you are exploiting vulnerabilities in human psychology. >> pretty interesting and unusual that this is the kind of campaign that is coming out now from apple shareholders. dagen: absolutely. you see a major investor trying to get ahead of a loom

i will be speaking at the ceo of merck, ken frazier courtesy of myelin, have airbrushed from the ceo celgene, mark ailes in a sea of quest diagnostics. also next our therapeutic ceos here as well. big three hours ahead. you don't want to miss a moment of it. we will be right back. the day after chemo might mean a trip back to the doctor's office, just for a shot. but why go back there, when you can stay home with neulasta onpro? strong chemo can put you at risk of serious infection. neulasta helps reduce infection risk by boosting your white blood cell count, which strengthens your immune system. in a key study, neulasta reduced the risk of infection from 17% to 1%, a 94% decrease. applied the day of chemo, neulasta onpro is designed to deliver neulasta the next day. neulasta is for certain cancer patients receiving strong chemotherapy. do not take neulasta if you're allergic to neulasta or neupogen (filgrastim). ruptured spleen, sometimes fatal as well as serious lung problems, allergic reactions, kidney injuries, and capillary leak syndrome have occurred. report abdominal or should

you will not hear from merck that this is what you must take. think this is very good news >> yeah, we don't want to over look that of these important advances in terms of cancer therapies. >> right, especially of what was talked about last week at the jp morgan conference, they pretty much laid out everything because it was a good interview with meg and the ceo, this is out of nowhere and i think it is going to propel the stock in the next level that's been really stalled out. >> you mention ed some of these dow components and the price target raised from boeing of 305 to 380 today >> their age factor is incredibly strong. the gtf engine, you cannot make it fast enough the oldest turn around is rather remarkable depreciation is not going to help very much >> the price target moves our materials. it is not moving 20 bucks, they're moving 50 bucks or 60 bucks. >> i think they'll find the next boeing >> will boeing be the next boeing >> look when you have a pipe that you cannot make fast enough, what does it tell you? it tells you are in the drive

boeing, merck, caterpillar and united tech.ing) (barry murrey) when you have a really traumatic injury, we have a short amount of time to get our patient to the hospital with good results. we call that the golden hour. evaluating patients remotely is where i think we have a potential to make a difference. (barry murrey) we would save a lot of lives if we could bring the doctor to the patient. verizon is racing to build the first and most powerful 5g network that will enable things like precision robotic surgery from thousands of miles away. as we get faster wireless connections, it'll be possible to be able to operate on a patient in a way that was just not possible before. when i move my hand, the robot on the other side will mimic the movement, with almost no delay. who knew a scalpel could work thousands of miles away? ♪ >>> good morning once again, everyone here's your cnbc news update nato saying the campaign against isis is changing from combat to stabilization. allies gathering for their first meeting of the year to anno

up 1.8%,oking at merck after the fda approved a merck and after zeneca partnered -- cancerneca partnered drug. travel is higher for a second day in a row, and microsoft with bullish comments out there. another record high for microsoft, so 20 straight for stocks. keep them going. julia: for more on today's market moves and what might come next week, we are joined by scott . great to have you on the show. even more excited to have you, because at the back end of last week, we were saying that a lot of analysts have been caught off guard because we have rallied so far this year, a lot of the 2018, and targets are quickly approaching, if not being surpassed. you are one of those who, last week, readjusted your forecast for equities. explain what you are for now? scott: the thing for us is our number that we had assumed had a 23% tax rate. we had a 53% right off of -- ff of capex. writeo our targets were forced higher, and after that adjustment, we were looking for an 8% return this year for the entire year, as you just mentioned. we are up 4% already. we do not want to annualized what we ha

merck soaring on positive lung and cancer trials. and united beating estimates merck higher by 6.5% united higher by 2.5%. the loser, ge. sources telling cnbc that a breakup of the company could come as soon as this spring. not helping the stock. still lower by nearly 4% after hitting all-time highs, big tech is losing its gains right now. google, netflix, microsoft, and apple giving up their gains. retail also weighing under armour, target, macy's, nordstroms deep in the red they had a very good run brian. >> thank you very much here's what else is happening. the final numbers out for online sales last year. as expected, it was another record year. according to adobe, the 2017 holiday season posted $108 billion worth of online sales. that's a jump of nearly 15% year over year. citi group says it will increase compensation for women and minorities in the u.s., the uk, and germany. they found disparity in pay after conducting surveys it's the first bank to respond to a shareholder push to disclose their gender pay gap. >> and nxp sayi

the biggest winner in the dow was merck after announcing positive news. the biggest loser was general electric ge shedding 3% merck leading the s&p while under armour was the biggest loser there. ua shed nearly 12% today a big day for the market overall when we had that 282 pop, the dow crossed 22,000 for the first time today that was just seven trading days after it first crossed 25k then reversed and finished by lower than ten points. what are your thoughts >> leaves open the question whether the market in a short-term basis emptied the tank it's been whistling higher, blowing through the signs, it's overdone, too much, too soon on a one-day basis after an opening pop, after a three-day weekend on no news, it seemed like it wasn't the smartest money bidding at the open. that doesn't mean this is some important reversal just means we might have gotten tired. >> michael, with your trading hat on, how tired are we are we going to look back on this morning's 26k run as a distant memory is there more of a decline to come, do you think >> there's some invinci

pharmaceutical giant merck has dragged the dow down during that timespan. general electr is not a big high priced stock anymore but it dragged 82 poi dow's performance. big blue, ibm. as we talk about the march for the next leg higher in the dow jones in average, we'll talking about whether or not e stocks can turn around or whether the momentum in shares like boeing, home depot and others can maintain that upside. for "nightly business r i'm dominic chu. >>> to the economy, where u.s. employers created 250,000 jobs last month, much more than expected. it i the latest report pointing to strength in the economy. and as steve liesman tells us, it's the economy that's playing an important role in the stock >> reporter: some stock market surges take flight on the hot air of just hopes and dreams. but this one seems to have some solid economic data keeping it afloat. we got more proof of that today with an adp report suggesting 250,000 jobs created in the private sector in december. that was far more than the consensus, and far more than economists expect for to

. >>> merck was the best performing component today. their blockbuster drug when used with two chemotherapy drugs was successful as a fires line for lung cancer. the results indicated the drug cocktail could help patients live longer and stop the disease from advancing, merck's6% in tr. the second best performing stock today was united health care. i topped expectations and raised its profit outlook for the year by more than 16% due to the corpor tax cut. the insurer also said it plans to speed up investments in technology that it hopes will cut customer costs. united health is the largest u. health insurer and the first to report fourth quarter profits. stock rose more than 1.5% on the trading session. >>> then there was general electric. it was the worst performing stock on the blue chip index today, falling nearly 3%. this after the company announced a $6 billion setback, and the ceo said something that was once thought unthinkable. he is thinking about a breakup. morgan brennan has our story. >> reporter: you mark the end of an era.

weather into south wales, and for north wales as things turned more mild in the afternoon sun missed and merckand what is left of the snow, any areas will end up right, a fair amount of cloud, this area of rain close to the south coast and certainly the channel islands so wet weather continuing and look at the temperatures for monday morning, 1— 10 degrees, much less chilly start. monday will bring the rain scraping perilously close to the south of england otherwise not a bad day, a fairamount of england otherwise not a bad day, a fair amount of cloud, some sunshine about, always patchy rain at times for hills and coast in the west. temperatures 5— ten. just the first sign of the milder air is winning out and it will continue to do so to the most part through the week ahead, something colder, never too far away from northern areas so temperatures in the north will tend to go up and down but not as cold as it has been, certainly mild further south, 12— 13, but with a mild air, we will see some wet and windy weather continuing our times through the week ahead. it is all from me for now. this is

mist, merck, drizzle, temperatures around 11 degrees. a mild evening in the south.we will bring more cloud backin of sunday, we will bring more cloud back in from the west. with that things will turn milder again, starting the day at ten, 11 degrees. mild south—westerly winds. trapped in that south—west airflow we will have this weather front. it essentially become stranded. it cannot move north or cells, instead it gets stuck, most likely over central and southern parts of scotland. to the north of that, some showers and brightness, to the south a lot of cloud, breeziness, and where the cloud breaks up, chiefly to the east of high ground, temperatures will respond, maybe up to 15 degrees. not bad for late january. the mild weather will get swept away on monday, this system pushing south, a cold front bringing outbreaks of rain. behind it, a cooler temperature. by wednesday we will be in cold air. a chillier feel for middle of the week. dues largely dry, and showers packing in from the north—west by wednesday. —— tuesday largely dry. more weather here in an hour. ——

>> the one big thing is both work and pfizer -- merck and pfizer -- nestle has said they are moving awaygary stuff. the ceo has been in the health care industry. more of buying the brands they bought last year, organic or health supplements, that kind of stuff. they don't need the money. mark: if you are hershey today, what are you thinking? >> you are not happy. hershey and ferrero were the last ones standing in that bidding process. with this deal, ferrero becomes the third -- how does this play out for us? they missed out on this u.s. confectionery business. they will be seeing what else they can do. mark: thank you for joining us. weing up in the next hour, will speak to the chief executive of nomad foods about his $275 million acquisition. vonnie: looking forward to that interview. time for our latest bloomberg business flash. shares of rolls-royce rising today. they are reviewing the future of the commercial y marine unit. revising the business from five operating units to three. google tightening up its youtube rules to clean up the video site for advertisers. youtube will impose

otherwise, we have merck trading higher on early results from its showing an medicine extended survival when used in combination with chemotherapy. amazon rising after it got an analyst price target of $1600. record.ares at a unitedhealth group coming up with its earnings, boosting its forecast for 2018 with a lower tax rate. those shares up 2% as well. the laggards, a combination of energy and materials here. mosaic lower. there's been bearish commentary -- credit suisse coming out saying there's too much positive sentiment on nitrogen. just big and southwestern downgraded to underperform from neutral -- chesapeake and southwestern downgraded to underperform from neutral. vonnie: thank you for that. we want to bring you more on that breaking news. nestle will sell its u.s. confectionery business to ferrero for $2.8 billion. nabila ahmed joining us for more. we have confirmation. about a shiftlly away from unhealthy snacks. nestle wanted to get out of this business. they've been steering away from chocolates and sugary sweets. they are now the leader in the consumer unit. the relatively

merck was singled out by the president in a critical tweet after mr.zier resigned from the president's manufacturing counci council. >> we continue to work with both the congress and the administration to try to do what's good for patients there are real issues out there for patients, there are real issues for the economy, jobs, innovation we continue to work effectively, i think, with the administration as well as with congress on those issues >> were you surprised or insulted when the president got personal with these tweets >> no, i can't say i was surprised. you know, i made my statement and the president made his statement in response. >> and we'll hear more throughout the day from the ceos of johnson & johnson, allergan, and on the 28th, cnbc will host our first ever healthcare conference, healthy returns, investing in healthcare innovation we will be featuring top government officials, ceos, innovators, as well as investors. you can find more information at cnbc.com/healthyreturns. >> so the merck stuff, when they say that most of those -- they

another mover is merck, jumping on news of positive results from a lung cancer trial. that is up 7 1/2%. we're watching general electric a different picture. the stock is under pressure. they cut the dividend. they're working on the company since late last year. it is down again 3 1/2%. the latest on that they expect to take a billion after-tax charge in the fourth quarter, reviewing ge capital insurance portfolio. so a charge will be taken there. another tough day for general electric. big picture, dow 26,000 in just he have seven days. we'll see whether or not we close above the market, up 160. neil: i ask you this every milestone but do they get nervous there? everyone likes stocks going up but though know eventually things go down. are they worried about it going down? >> interesting you ask that. that would be chatter you expect to here in light of run-up. that is not what they're talking about. they feel optimistic. looking to corporate profits. now earnings season. we're seeing positive earnings. we've done so well despite all the news, whether north korea or, i

okay so one of merck leading military historian and foreign policy analysts i should have said first that there will be a book signing with boot following the program. and yes, i'll say it again we're thrilled to welcome him become to the new york historical society he's the patrick and fellow security studies at the counsel on foreign relations. and he's a regular contradict tore to usa today, "new york times," and many other publications. he's author of several widely acclaimed books of military history, his welcometured on behalf of the u.s. state department, with at end at many military institution and he's advisorred commanders in iraq and afghanistan. his new book is road not taken, edward dale and american tragedy in vietnam. it's an honor for us to welcome general david h. petraeus back to the new york historical society as moderator for this evening's program. general petraeus u.s. army retired is currently a partner in global investment firm kkr, and chairman of the kkr global institute. he's also the judge with me professor at the university of southern california. general

. ♪ >> if you take a look at the bloomberg and the various business lines of merck, vaccines in blue,th in orange, and pharmaceuticals in white. overall, what you are looking at is tepid, if any, growth for the various revenue lines, particularly when you put them all together. juliette: there are about 30,000 functions on the bloomberg, and we always enjoy showing you our favorites on bloomberg television. maybe they will become your favorites. here's another function will find useful, q uic go. it will take you to quick takes, where you can get fast insight into timely topics. here is one from this week. >> used to be when a colleague emailed you to say they are working from home, you might not have envisioned the most productive day. maybe he was doing some personal chores. maybe he had a bit too much to drink. maybe he was just slacking off. >> uh, what's your dad's job again? >> but telecommuting is legit. currently, over 60% of u.s. companies provide the option, and it is often promoted as an extra perk to attract and retain talent, allowing companies to consider candidates in d

with lyft and disrupters can accelerate the pace of drug development maderna is collaborating with merckrazeneca to tackle everything from vaccines to cancer treatments. so which will be the next partners cbs is ak accepting nominations for the 2018 disrupter 50 list for dedaltails, go to cnbc.com. >> if one of them eventually goes public, won't be the former first one that gets to the public market. as for the rest of the day, we'll watch the head loons coming out of davos, evening time there and two more names that are highly leveraged to trade in dollar discussions. >> a lot of industrial earnings today. those are going to continue tomorrow as well starting to get a lot of defense names. also honey well on friday will be b closely watched after united technologies and ge today. >> let's get to the judge and the half >>> our top trade, euphoria overload why some are getting just too optimistic now our risk to the rally rising and what does it mean? with us today, steve weiss, pete na najarian kooefen o'leary and richard fisher, the former dallas fed president an a cnbc contributor. we

. >>> merck's ceo speaks out. we'll bring i his commenyou his straig comments straight ahead. >>> and the one sector that could see hot returns in these cold temperatures. it's tuesday, november 9, 2018 "worldwide exchange" begins now. good

can i just jump in, you really see the extent to which the parties are representing two different merck's in thamericas in this. there are not only a meaningful number of daca recipients. but very few republicans represent states or districts with a large number of immigrants to begin with donald trump won 26 of 30 with the lowest. the same is true with the senate. for democrats it is largely the reverse. they don't feel the immediate pressure, many of them, to deal with this issue that democrats and some republicans do who are aware. on the other hand, they have those kids and those families more broadly in their districts. the reality, as chris noted, 90% of the country roughly wants the d.r.e.a.m.ers to be allowed to stay. to some extent, democrats are willing to call their bluff. are republicans willing to stand by and let the president start deporting a meaningful number of these kids in app election year. >> let's look at the moment who the public would blame for the shutdown. this is not an easy answer for the people who are looking for an answer whether to do it. they say they wou

leading the way, ge, ibm, dow, dupont, merck, american express. we say hello to dow 25,000, liz.unless something happens in the next 3 minutes and 20 seconds. looking at the dollar and bitcoin as we head into the closing bell. bitcoin is down slightly. so many people in 2018 want to ride the cryptocurrency wave who are afraid to dive in completely guess what of all things the old school dow may have an easy fix for you. one that lets you buy a stock, then get the bit-coin related information for free. we bring in our buddy chris bert. what stock is it? >> liz, ibm. you buy one which is the mainframe business, look what you get free? you get block shane. you get ai, and you get the cloud. so how can you resist. liz: it is toggling between general electric as the best performer on this dow 25,000 day. do you think some has to do with the fact people are looking through different prism at ibm, maybe its not so old school and left behind? >> absolutely. at these prices they're realizing after 20 plus quarters of no growth, this company is actually made a turn. gina rometty is doing a

but merck, eli lilly, so many people out here. the reaction on twitter has been so forceful. together with tax reform. we give you tax reform. you get out of production and trying to make the drugs. people very upset, depressed about this. not enjoying it. the stock though barely moved today. wall street. shrugged their shoulders and kept going on. >> shepard: seems to be one direction. >> that would be up. >> shepard: thank you, gerri. president trump expected to speak minutes from now about farmers and rural america. this is the president arriving in nashville earlier in this hour. the white house says the president will head to atlanta for tonight's college football championship game between the alabama crimson tide and the georgia bulldogs. as we would say down south, sec, sec, sec! just deal with it. deal with it. i have no room to speak over here. we have a georgia bulldog over here and an absent crimson tide over there. roll dogs! the lexus es. with standard technology like lexus safety system plus. the lexus es, and es hybrid. experience amazing at your lexus dealer.

dowing laggards here, goldman sachs, walt disney, merck, boeing, as airbus got a deal boeing did not get. we see that dragging on major averages. homebuilders, tolle brothers hit a new high but with a number in december saw a drop for home building that was the worst december in monthly number. was a drop hadn't seen that since november of 2016, entire year for 2017. home building housing starts in particular did well. building permits not indication what happened moving forward. here is look. the group is under pressure. last but not least watching viacom and cbs. sumner redstone split viacom and cbs in decade ago. failed attempt to recombine them. sherry road ten, controlling shareholder over at cbs has been in, there is viacom. we'll continue to watch this developing story in the media world. back to you. david: i said phil flynn will be here on commodities. he is not. let me told you gold took a major hit. a big hit for the gold bugs. thank you very much. melissa? melissa: it is the economy stupid. president trump taking a victory lap on tabs reform touting the effect of tax cuts

top to bottom but in the end, in fact we finished down about 10 points taking a look at what we saw merck, united health, coca cola and we saw good names, united health, citigroup, and did show strength overall on the downside here is a look at ge was the one we were focusing on but looking at chevron, disney those came under pressure and ge in particular taking a charge of $6.2 billion, and almost more than 11 billion depending on how you figure it and this is all in their insurance portfolio and that dropped about 3%, big picture and then we saw the tech titans and they finished mixed but these hit all-time highs so what happened to the big rally of 280 points? well i won't say that some people are just saying that we took some profits off the table. we had some areas we wanted to sell don't forget we had 26,000, right? and dow 19,000 right after the president's election in november of 2016, and its been all up arrows since then so it's okay to take a little off the table and also we have government shutdown looming and some people have had some chatter about that and energy pulled back

are you considering an acquisition of that business or merck's business >> sure, megan thank you forquestion. there is absolutely no new news on the consumer deal at all. we are one of the world leaders in consumer health care. we have a strong track record of integrating businesses successfully, so you'd expect us to have a look at it, but, frankly, we don't need to do this deal. we certainly won't overpay for it, and nothing is going to cut across our number one priority, which is our pharma business and really focusing on building that pipeline for the next wave of growth >> and talking about r&d, your hiring of hal baron, that's got a lot of people talking this weekend. people are excited about him he's considered a very heavy hitter in this industry. does that signal you're going to make big moves in research and development, licensing things in, changing things even more? >> of course i'm absolutely thrilled hal is coming to join us, and you're right. again, it is a clear demonstration of the fact we're prioritizing pharma and r&d, because this is, you know, the point of our in

it was offered at a organization called work merck. don't get me wrong, you have killer tech mrs.u still don't have fios. ok? fios is a 100% fiber-optic network, literally engineered for streaming. good advice. i've also got some ideas on a better cereal selection, which i will keep to myself. experience netflix on the 100% fiber-optic network made for streaming. switch to fios and get a year of netflix on us with a two-year agreement. the linc. all traffic is being pushed off at broad street because of this accident. a two-vehicle crash that has injured three people. the vehicles slammed into each other a little before 5:00 this morning. one person was thrown from one of the vehicles. two others were also taken to the hospital. one is in critical condition. the other is stable. stick with action news for updates on this breaking news. >> 7:30 your time. eagles fans are fired up for tonight's nfc championship game. the eagles and vikings facing off and police have a plan of their own. we've got live team coverage for you up next. >> let's get right to your game day forecast with m

liz: and watch this, prices of pharma stocks and biotechs coming down, you can see pfizer, merck, eli down from 2% to down 4.63%. one-two punch from the president, and amazon berkshire hathaway matchup killing the names. that was yesterday. today you have the aftermath what the president said. with eli lilly getting hurt there. look at celgene, amgendown, biogen lower, 1 1/2. let's bring in byron and boyd. boyd, to you first, pharma, not too happy with the president and nobody else might be. >> pharma will have more of its fair share of problems, which is a good thing because they've been employing an army of lobbyists which is collusion of the swamp which they're going to take a swing at. you saw in the press conference something important, liz, that not only was this about big companies doing well but getting it down to the little guy which is the messaging, getting it down to the small businesses, not just the big companies doing well and getting big bonuses to the family-owned business. this was a message that met the policy which is pretty rare for the administration thus far. li